Search News Archives
VIEW THE LATEST ISSUE
Microscopy | Image Analysis
IT Solutions and Laboratory Automation
Conferences | Events
Beckman Coulter Life Sciences and AmoyDx Sign Application Development Agreement for the Biomek NGeniuS System
Companies around the world continue to show strong interest in the Biomek NGeniuS Next Generation Library Prep System from Beckman Coulter Life Sciences and seek to develop demonstrated applications on this easy-to-use new NGS automation platform, which reduces errors and minimizes hands-on time.
Following a successful unveiling to the media and lab researchers at last month’s Society for Laboratory Automation and Screening (SLAS) International Conference & Exhibition in Boston, the company announces it has entered into an application development agreement with AmoyDx.
The collaboration will enable AmoyDx, an innovative commercial-stage in vitro diagnostic (IVD) company, to develop new demonstrated applications on the Biomek NGeniuS Liquid Handling System*. The purpose-built liquid handler for NGS library preparation reduces manual transfers and the traditionally labor-intensive process of library construction.
“We are committed to accelerating application development and providing new NGS applications to further propel the research journey of our customers,” said Calvin Cortes, Biomek NGeniuS System Product Manager. “This is part of a robust series of development agreements, which speaks to the strength of the Biomek NGeniuS System coupled with the automation library preparation portfolio of partners like AmoyDx.”
“To benefit tumor patients globally, and to bring value to customers, is our unwavering pursuit,” said Jiemin Luo, the Rotating General Manager of AmoyDx. “Together with Beckman Coulter Life Sciences, AmoyDx will bring advanced and reliable automated library preparation solutions for accelerating and improving quality and efficiency of NGS research.”
As part of the partnership agreement, AmoyDx will develop applications specifically designed for the Biomek NGeniuS liquid handler, which will be available to all users via a first-of-its-kind electronic application library.
The Biomek NGeniuS System is scheduled to launch in the second quarter of 2022.
About Amoy Diagnostics Co., Ltd.
Amoy Diagnostics Co., Ltd. is a pioneer and globally leading company in the field of molecular diagnostics for precision oncology, focusing on companion diagnostics product development and commercialization. A rich product portfolio has been established with more than twenty products approved by China NMPA, EU authority, Japan MHLW, South Korea MFDS, etc. Patients in more than 60 countries are benefiting from AmoyDx products. With multiple technological platforms and full capability for companion diagnostics product development and commercialization, AmoyDx has become an important diagnostics partner of many pharmaceutical companies over the globe.
About Beckman Coulter Life Sciences
Life sciences. Research. Precision manufacturing. If your life’s calling is in any of these or related fields, you need to know Beckman Coulter Life Sciences. Our mission is to empower those seeking answers to life’s important scientific and healthcare questions. Since 1935, the Beckman name has been synonymous with technologies that simplify and automate complex biomedical testing. Decades later, our global organization also came to embody the scientific legacy of the Coulter name. Today, Beckman Coulter Life Sciences is a trusted, worldwide resource for tools to help optimize research and manufacturing efficiency. Centrifuges. Particle counters/analyzers. Automated liquid handlers. Flow cytometers. Genomic reagents. All these products—and many more—continue to make a difference in people’s lives by improving the productivity of dedicated scientists, quality control experts and others. Wherever people need answers, from prestigious universities and major pharmaceutical companies, to small biotech startups, food/beverage and electronics manufacturing facilities, you can find Beckman Coulter Life Sciences.
Recent news from Beckman Coulter